Å·ÃÀAV

Introduction

The Commissioner of the US FDA has stated the agency will be more enforcement oriented and quicker to issue Warning Letters. This presentation will review current enforcement practices of the US FDA with actual Warning Letters recently issued to medical device companies. We will explore how the company failed to meet FDA expectations in response to inspection and other violations. In the presentation we will attempt to determine what response by the manufacturer may have prevented the issuance of the Warning Letter. We will look at improvements to the Quality System as well as responses to the FDA-483 that was issued to the manufacturer following the inspection. The presentation will show techniques that may be used with publically available information to follow FDA's current practices and predict how the manufacturer may act to avoid a Warning Letter.

Useful links

Venue

Online Training Webinar

Online Training Webinar, United States

Useful links

Organised by

GlobalCompliancePanel

Contact information

Mr Manzoor
United States of America
800-447-9407
Contact us by email

---